Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene,
including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and …

Abstract Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary
tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling complex, is …

Purpose: There is increasing use of neoadjuvant chemotherapy in the management of
localized pancreatic ductal adenocarcinoma (PDAC), yet there are few validated biomarkers …

Outcomes for patients with advanced pancreatic cancer have improved in the past 12 years,
mainly because of progress made in systemic therapies. New treatment strategies for …

PURPOSE: Testing for pathogenic variants can aid in oncologic risk stratification and
identification of targeted therapies. Despite known disparities in access to prostate cancer …

Background Senaparib is a novel, selective poly (ADP‐ribose) polymerase‐1/2 inhibitor with
strong antitumor activity in preclinical studies. This first‐in‐human, phase 1, dose‐escalation …

As a critical tumor suppressor, PTEN has gained much attention in cancer research.
Emerging evidence suggests an association between PTEN status and clinical outcome in …

Abstract Background Somatic pathogenic variants (PVs) in homologous recombination DNA
repair (HR)-related genes found in high-grade serous ovarian carcinomas (HGSC) are not …